VTT is launching an extensive EU project called ETHERPATHS, studying the effects of dietary effects mediated by gut microbiota on lipid metabolism. The aim is to accelerate the development of health-promoting foods. The project develops computer assisted models with which food companies and research institutions, for instance, will be able to predict the effects of foods in the body.

The Healthcare and Science business of Thomson Reuters has released the white paper, "The Five Myths of Generic Competition," highlighting what originator pharmaceutical and biotech companies can do to improve their forecasting of the likely timing, source and intensity of competition from generic drugs.

Deutsche Zeitschrift für Klinische Forschung (DZKF) portal, developed by Geelen & Geelen Beratung für medizinisch-wissenschaftliche Projekte GmbH, now is available in English. The portal is password protected and accessible only by medical scientific professionals, it allows to publish and read multimedia-format information and send others the related web link(s).

Pharmaceutical product sites are an important component of an overall brand strategy and can serve as a brand extender for consumers - providing an engaging brand experience that may not be fully realized in the time and space constraints of traditional media.

More than ever, type 1 and type 2 diabetes patients are turning to online channels to research treatment and product information, to seek advice and support from others, and to manage their condition. According to pharmaceutical and healthcare market research company Manhattan Research's Cybercitizen Health™ study, nine out of ten online diabetes patients use the Internet to research health information, and two-thirds use the Internet to access pharmaceutical product information.

A new survey released by IBM (NYSE: IBM) and Silico Research reveals that if biopharmaceutical - or life-sciences - companies fail to collaborate, they risk costly delays in the production of new medicines, medical devices, diagnostics and support services.

New research has helped to explain why patients being treated with antiretroviral drugs for HIV experience a greater incidence of heart attacks. The research was presented by doctors and researchers from the School of Medicine and Medical Sciences at University College Dublin, the Mater Misericordiae University Hospital in Dublin and the Royal College of Surgeons in Ireland at the Retroviral Conference in Montreal, Canada, on 11 February.